Clinical Trial

Current Status of BTKi Treatment for CLL/SLL in China

Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 18, 2024 (before its estimated February 12, 2025 completion). Its status may not reflect the trial's current state.
Summary
BTKi has become the standard treatment regimen for CLL/SLL，there is a lack of large-scale real-world studies on the use status and related influencing factors of BTK inhibitors. Therefore, we plan to conduct this multicenter retrospective cross-sectional study to understand the current situation of BTK inhibitor treatment for CLL/SLL patients in China and the related influencing factors, and to explore more suitable treatment patterns based on this.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06508684
Lead Sponsor The First Affiliated Hospital with Nanjing Medical University
Conditions CLL/SLL
Enrollment 1,000 participants
Start Date 2024-07-13
Primary Completion 2025-02-12 (estimated)
Study Completion 2025-07-12 (estimated)
Updated on ClinicalTrials.gov 2024-07-18